Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on January 7, 2019. The registrant is incorporated in Delaware and is designated as an emerging growth company. The filing serves as a Regulation FD disclosure to distribute a corporate presentation intended for use in investor meetings.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to announce the availability of a corporate presentation rather than a financial report containing quantitative data.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The primary event is the release of a corporate presentation (Exhibit 99.1) for investor relations purposes.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in Item 7.01 and the attached Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the content is not subject to the liabilities of that section nor incorporated by reference into other filings, except as expressly set forth by specific reference. No specific guidance, risks, or contingencies are enumerated in the body of this 8-K.
Investor Verification Checklist
- Verify the content of the corporate presentation attached as Exhibit 99.1 on the company's investor relations website (http://aerpio.com).
- Confirm that the presentation is not legally considered "filed" material under Section 18 of the Exchange Act.
- Note the discrepancy between the request metadata (Whitehawk Therapeutics) and the filing registrant (Aerpio Pharmaceuticals, Inc.).